This protocol for CRISPR–Cas9 editing in primary mouse T cells enables studies of gene-edited CAR T cells in immune-intact cancer models, enabling users to explore the impact of a given gene deletion on CAR T cells within a natural tumor microenvironment.
- Puneeth Guruprasad
- Ranjani Ramasubramanian
- Marco Ruella